Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
GAITHERSBURG, Md., April 25, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has presented preliminary results supporting its Acuitas Rapid Test in development to detect antibiotic resistant genes and the use of predictive algorithms from its Acuitas Lighthouse® Knowledgebase to predict antibiotic susceptibility. The results were presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria.
The poster, titled “Prediction of antibiotic resistance in Escherichia coli from resistance genes,” compared phenotypic antibiotic susceptibility testing (AST) with the emerging capabilities of Lighthouse Knowledgebase informatics to predict antibiotic resistance using resistance genes from bacterial isolates. The results of testing over 1,900 E. coli isolates with PCR yielded strong prediction of phenotypic antibiotic resistance for seventeen antibiotics representing seven antibiotic classes with accuracies ranging from 77% to 97%. Resistance for 12 of the antibiotics were predicted with 90% or greater accuracy.
A second poster, titled “Rapid outbreak detection of multidrug-resistant organisms using resistance gene profiles,” illustrated the potential to detect hospital pathogen outbreaks by clustering isolates based on resistance gene profiles using a PCR-based test. Outbreak clusters of P. aeruginosa and E. coli were accurately discriminated using multiple resistance genes, thereby demonstrating that a multiplexed PCR-based test has potential to be a rapid, accurate, and efficient method for surveillance of multidrug-resistant organisms.
“In the preliminary results presented at ECCMID, our Acuitas technology demonstrated the ability to rapidly and accurately predict antibiotic susceptibility using resistance gene profiles,” said Evan Jones, Chairman and CEO of OpGen. “The development of our first Acuitas Rapid Test to detect resistance genes for interpretation by our Acuitas Lighthouse informatics is underway. The data presented at ECCMID support the potential clinical utility of this exciting new technology.”
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
Contact: OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 [email protected] [email protected] Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong 781-591-3443 [email protected]
